TR201818775T4 - Ksantin oksidaz inhibitörü olarak azol benzen türevi kristali. - Google Patents

Ksantin oksidaz inhibitörü olarak azol benzen türevi kristali. Download PDF

Info

Publication number
TR201818775T4
TR201818775T4 TR2018/18775T TR201818775T TR201818775T4 TR 201818775 T4 TR201818775 T4 TR 201818775T4 TR 2018/18775 T TR2018/18775 T TR 2018/18775T TR 201818775 T TR201818775 T TR 201818775T TR 201818775 T4 TR201818775 T4 TR 201818775T4
Authority
TR
Turkey
Prior art keywords
xanthine oxidase
oxidase inhibitor
benzene derivative
derivative crystal
azole benzene
Prior art date
Application number
TR2018/18775T
Other languages
English (en)
Inventor
Kawana Asahi
Miyazawa Yuki
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of TR201818775T4 publication Critical patent/TR201818775T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Gut, hiperürisemi ve benzeri için bir terapötik ajan veya profilaktik ajan olarak faydalı olan 2-[4-(2,2-dimetilpropoksi)-3-(1H-1,2,3,4-tetrazol-1-il)fenil]-4-metil-1,3-tiyazol-5-karboksilik asidin kristalleri sağlanmıştır.
TR2018/18775T 2014-07-30 2015-07-29 Ksantin oksidaz inhibitörü olarak azol benzen türevi kristali. TR201818775T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014155031 2014-07-30

Publications (1)

Publication Number Publication Date
TR201818775T4 true TR201818775T4 (tr) 2019-01-21

Family

ID=55217594

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/18775T TR201818775T4 (tr) 2014-07-30 2015-07-29 Ksantin oksidaz inhibitörü olarak azol benzen türevi kristali.

Country Status (30)

Country Link
US (1) US9815826B2 (tr)
EP (1) EP3176165B1 (tr)
JP (1) JP6230713B2 (tr)
KR (1) KR20170033321A (tr)
CN (1) CN106536519B (tr)
AR (1) AR101363A1 (tr)
AU (1) AU2015297489B2 (tr)
BR (1) BR112017001659A2 (tr)
CA (1) CA2955485A1 (tr)
CY (1) CY1120933T1 (tr)
DK (1) DK3176165T3 (tr)
ES (1) ES2693382T3 (tr)
HR (1) HRP20181789T1 (tr)
IL (1) IL250144B (tr)
LT (1) LT3176165T (tr)
MX (1) MX370375B (tr)
MY (1) MY179339A (tr)
NZ (1) NZ729045A (tr)
PH (1) PH12017500123B1 (tr)
PL (1) PL3176165T3 (tr)
PT (1) PT3176165T (tr)
RS (1) RS57797B1 (tr)
RU (1) RU2675854C2 (tr)
SA (1) SA517380786B1 (tr)
SG (1) SG11201700742UA (tr)
SI (1) SI3176165T1 (tr)
TR (1) TR201818775T4 (tr)
TW (1) TWI687418B (tr)
WO (1) WO2016017696A1 (tr)
ZA (1) ZA201700491B (tr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201300552D0 (en) * 2013-01-14 2013-02-27 Moog Bv Motion simulator
WO2016017826A1 (ja) * 2014-07-30 2016-02-04 帝人ファーマ株式会社 キサンチンオキシダーゼ阻害薬

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2073981C (en) * 1990-11-30 2002-01-08 Shiro Kondo 2-arylthiazole derivatives and pharmaceutical composition thereof
JP3194964B2 (ja) * 1995-04-07 2001-08-06 帝人株式会社 臓器または組織保護剤
JP2002105067A (ja) 2000-09-28 2002-04-10 Teijin Ltd ２−フェニルチアゾール誘導体、およびそれを有効成分とする医薬組成物
US7001922B2 (en) * 2002-11-14 2006-02-21 Celmed Oncology (Usa), Inc. Peptide deformylase activated prodrugs
US7947707B2 (en) 2005-10-07 2011-05-24 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
WO2008126770A1 (ja) 2007-04-05 2008-10-23 Astellas Pharma Inc. トリアリールカルボン酸誘導体の製造方法
WO2008126899A1 (ja) * 2007-04-11 2008-10-23 Kissei Pharmaceutical Co., Ltd. ５員環へテロ環誘導体及びその医薬用途
WO2010018458A2 (en) 2008-08-12 2010-02-18 Crystalgenomics, Inc. Phenol derivatives and methods of use thereof
WO2010128163A2 (en) 2009-05-08 2010-11-11 Pike Pharma Gmbh Small molecule inhibitors of influenza a and b virus and respiratory syncytial virus replication
US20130190366A1 (en) 2010-02-19 2013-07-25 Cadila Healthcare Limited Substantially pure salts of febuxostat and processes for preparation thereof
WO2011139886A2 (en) 2010-04-29 2011-11-10 Dr. Reddy's Laboratories Ltd. Preparation of febuxostat
TWI606048B (zh) * 2013-01-31 2017-11-21 帝人製藥股份有限公司 唑苯衍生物

Also Published As

Publication number Publication date
PH12017500123A1 (en) 2017-05-29
BR112017001659A2 (pt) 2018-01-30
KR20170033321A (ko) 2017-03-24
ZA201700491B (en) 2018-04-25
AU2015297489B2 (en) 2019-09-19
DK3176165T3 (da) 2019-01-02
PL3176165T3 (pl) 2019-03-29
JP6230713B2 (ja) 2017-11-15
RS57797B1 (sr) 2018-12-31
MX2017000513A (es) 2017-04-27
SI3176165T1 (sl) 2018-11-30
US20170210735A1 (en) 2017-07-27
MX370375B (es) 2019-12-11
SA517380786B1 (ar) 2021-01-17
RU2017106058A3 (tr) 2018-08-28
RU2017106058A (ru) 2018-08-28
IL250144B (en) 2019-11-28
EP3176165A4 (en) 2017-06-07
SG11201700742UA (en) 2017-03-30
CY1120933T1 (el) 2019-12-11
HRP20181789T1 (hr) 2018-12-28
IL250144A0 (en) 2017-03-30
CN106536519A (zh) 2017-03-22
PT3176165T (pt) 2019-01-10
CA2955485A1 (en) 2016-02-04
PH12017500123B1 (en) 2017-05-29
NZ729045A (en) 2022-05-27
TW201619153A (zh) 2016-06-01
MY179339A (en) 2020-11-04
TWI687418B (zh) 2020-03-11
AU2015297489A1 (en) 2017-03-09
LT3176165T (lt) 2018-11-26
AR101363A1 (es) 2016-12-14
EP3176165A1 (en) 2017-06-07
WO2016017696A1 (ja) 2016-02-04
ES2693382T3 (es) 2018-12-11
EP3176165B1 (en) 2018-09-26
CN106536519B (zh) 2019-03-29
JPWO2016017696A1 (ja) 2017-04-27
US9815826B2 (en) 2017-11-14
RU2675854C2 (ru) 2018-12-25

Similar Documents

Publication Publication Date Title
DK3684767T3 (da) Heterocykliske forbindelser som pad-inhibitorer
CU24462B1 (es) Derivados de feniltriazol sustituido con hidroxialquilo
UY35998A (es) 1-(3-(tert-BUTIL)1-(p-TOLIL)-1H-PIRAZOL-5-IL)-3-(4-((2-((6-ETILPIRAZIN-2-IL)AMINO)PIRIDIN-4-IL)METOXI)NAFTALEN-1-IL) UREA Y SUS SALES DERIVADAS FARMACÉUTICAMENTE ACEPTABLES, COMO INHIBIDORES DE P38 M AP QUINASA
AR089818A1 (es) Inhibidor de la quinasa que regula la señal de la apoptosis
BR112017006420A2 (pt) derivados de ácido borônico
MX2019005565A (es) Inhibidores de urat1 y sus aplicaciones.
EA201990333A1 (ru) Соединения, композиции и способы лечения или предотвращения симптома, ассоциированного с подагрой или гиперурикемией
TR201818775T4 (tr) Ksantin oksidaz inhibitörü olarak azol benzen türevi kristali.
TR201902314T4 (tr) Azol benzen türevi ve bunun kristali.
NZ716494A (en) Processes and intermediates for the preparation of a pde10 inhibitor
EP3749647C0 (en) N-(5-(PHENYL)-1H-PYRAZOL-3-YL)-1H-INDOL-5-AMINE DERIVATIVES AS TNIK INHIBITORS FOR THE TREATMENT OF CANCER
WO2015173659A3 (en) N-(3-oxo-2,3-dihydro-1 h-pyrazol-4-yl)-4,5-dihydronaphtho[2,1 -d]isoxazole-3-carboxamide derivatives and related compounds as smurf-1 inhibitors for the treatment of pulmonary arterial hypertension (pah)
EP3802530C0 (en) HETEROCYCLIC COMPOUNDS AS CLASS II PHOSPHOINOSITIDE 3-KINASE INHIBITORS
EP3816158C0 (en) BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS IDH1 INHIBITORS
CO2018000953A2 (es) Asociación entre la 3 - [(3 - {[4- (4-morfolinilmetil) -1h-pirrol-2-il] metilen} -2-oxo-2,3-dihidro-1h-indol-5-il) metil ] -1,3-tiazolidina-2,4-diona y un inhibidor de la tyr quinasa del egfr
ES2723429T3 (es) Formulación de nanopartículas que comprende un inhibidor de mPGES-1
AR101362A1 (es) Derivado de azol benceno y forma cristalina del mismo
UA98919U (ru) 4-этил-3-(феноксиметил)-5-((2-((5-феноксиметил)-4-фенил-4н-1,2,4-триазол-3-ил)тио)этил)тио)-4н-1,2,4-триазол, проявляющая диуретическую активность
TH168006B (th) สารอนุพันธ์เอโซล เบนซีน และรูปผลึกของสารนั้น
UA114081U (uk) 5-(2-(4-(диметиламіно)бензиліден)гідразиніл)-4-феніл-4h-1,2,4-триазол-3-тіолу гідрохлорид, що стимулює ріст пшениці озимої
UA88738U (uk) 5-(гептилтіо)-3-(феноксиметил)-1н-1,2,4-тріазол, що виявляє антигіпоксичну активність
BR112016022974A2 (pt) derivados de 2,4-tiazolidinadiona no tratamento de distúrbios do sistema nervoso central
UA93722U (uk) Похідне 3-тіо-1,2,4-триазолу, що проявляє туберкулостатичну дію
UA98923U (ru) 3-((2-хлорэтил)тио)-4-этил-5(феноксиметил)-4н-1,2,4-триазола, проявляющей диуретическую активность
UA98156U (uk) 2-((5-(адамантан-1-іл)-4-феніл-4н-1,2,4-триазол-3-іл)тіо)-n'-(2-нітробензиліден)ацетогідразид, який проявляє антигіпоксичну активність